Results of Using Different Brain Reperfusion Methods in Patients with Acute Ischemic Stroke

Acute ischemic stroke (AIS) occupies one of the leading places in the structure of disability and mortality in adult population throughout the world, which causes a significant social and economic burden of this pathology. Recent advances in AIS diagnosis and treatment have significantly reduced mortality and improved functional outcomes in patients. However, categories of patients with unsatisfactory results and complications of reperfusion therapy still remain. In some of them, mortality may exceed the overall rate. To this day, there are controversial aspects in determining indications and choosing the preferred method of cerebral reperfusion. The presented cases describe the results of using thrombolytic therapy and thromboextraction in AIS patients of different age groups. The importance of various neuroimaging methods (multislice computed tomography, computed angiography, duplex ultrasound of extra- and intracranial arteries) for timely diagnosis and determination of optimal revascularization tactics was noted.

1. Shamalov NA, Stakhovskaya LV, Klochikhina OA, et al. An analysis of the dynamics of the main types of stroke and pathogenetic variants of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2019; 119(3): 5–10 (in Russ). https://doi.org/10.17116/jnevro20191190325.

2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24): 1581–7. https://doi.org/10.1056/NEJM199512143332401.

3. Hacke W, Kaste M, Fieschi C, еt al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274(13): 1017–25.

4. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998; 352(9136): 1245–51. https://doi.org/10.1016/s0140-6736(98)08020-9.

5. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999; 282(21): 2019–26. https://doi.org/10.1001/jama.282.21.2019.

6. Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012; 379(9834): 2352–63. https://doi.org/10.1016/S0140-6736(12)60768-5.

7. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13): 1317–29. https://doi.org/10.1056/NEJMoa0804656.

8. Mateen FJ, Buchan AM, Hill MD. Outcomes of thrombolysis for acute ischemic stroke in octogenarians versus non agenarians. Stroke. 2010; 41(8): 1833–5. https://doi.org/10.1161/STROKEAHA.110.586438.

9. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019: 50(12): e344–418. https://doi.org/10.1161/STR.0000000000000211.

10. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2012; 375(9727): 1695–703. https://doi.org/10.1016/S0140-6736(10)60491-6.

11. Saver JL, Levine SR. Alteplase for ischaemic stroke-much sooner is much better. Lancet. 2010; 375(9727): 1667–8. https://doi.org/10.1016/S0140-6736(10)60634-4.

12. Hasan TF, Hasan H, Kelley RE. Overview of acute ischemic stroke evaluation and management. Biomedicines. 2021; 9(10): 1486. https://doi.org/10.3390/biomedicines9101486.

13. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2012; 363(9411): 768–74. https://doi.org/10.1016/S0140-6736(04)15692-4.

14. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after Intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013; 368(10): 893–903. https://doi.org/10.1056/NEJMoa1214300.

15. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015; 372(11): 1019–30. https://doi.org/10.1056/NEJMoa1414905.

16. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016; 387(10029): 1723–31. https://doi.org/10.1016/S0140-6736(16)00163-X.

17. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018; 378(1): 11–21. https://doi.org/10.1056/NEJMoa1706442.